The Rhabdomyosarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Rhabdomyosarcoma. Buy the report here.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued products.
GlobalData tracks 71 drugs in development for Rhabdomyosarcoma by 64 companies/universities/institutes. The top development phase for Rhabdomyosarcoma is phase ii with 26 drugs in that stage. The Rhabdomyosarcoma pipeline has 63 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Rhabdomyosarcoma pipeline products market are: Pfizer, Ipsen and Eisai.
The key targets in the Rhabdomyosarcoma pipeline products market include Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 184.108.40.206), Vascular Endothelial Growth Factor Receptor 1 (Fms Like Tyrosine Kinase 1 or Tyrosine Protein Kinase Receptor FLT or Tyrosine Protein Kinase FRT or Vascular Permeability Factor Receptor or VEGFR1 or FLT1 or EC 220.127.116.11), and Vascular Endothelial Growth Factor Receptor 3 (Fms Like Tyrosine Kinase 4 or Tyrosine Protein Kinase Receptor FLT4 or VEGFR3 or FLT4 or EC 18.104.22.168).
The key mechanisms of action in the Rhabdomyosarcoma pipeline product include Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 22.214.171.124) Inhibitor with seven drugs in Phase II. The Rhabdomyosarcoma pipeline products include 11 routes of administration with the top ROA being Oral and 13 key molecule types in the Rhabdomyosarcoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy, and radiation therapy.
For a complete picture of Rhabdomyosarcoma’s pipeline drug market, buy the report here.